Mesial temporal sclerosis after posterior reversible encephalopathy syndrome.
Neither intrathecal methotrexate nor posterior reversible encephalopathy syndrome has previously been reported to result in mesial temporal sclerosis. Described here is the case of a boy with no risk factors for mesial temporal sclerosis who presented with posterior reversible encephalopathy syndrome and partial complex seizures 8 days after initiation of intrathecal methotrexate for treatment of Burkitt lymphoma, and who ultimately progressed to intractable temporal lobe epilepsy due to left mesial temporal sclerosis.
Aboian
Mariam S
MS
Mayo Medical School, Rochester, Minnesota, USA.
Junna
Mithri R
MR
Krecke
Karl N
KN
Wirrell
Elaine C
EC
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001927:Brain Diseases / Q000209:etiology* / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000473:pathology; D002648:Child; D038524:Diffusion Magnetic Resonance Imaging; D004833:Epilepsy, Temporal Lobe / Q000209:etiology / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D012598:Sclerosis; D012640:Seizures / Q000209:etiology / Q000473:pathology; D013577:Syndrome; D013702:Temporal Lobe / Q000187:drug effects / Q000473:pathology
D000970:Antineoplastic Agents; D008727:Methotrexate